|
|
| ^ EARS: Intraday Hourly Forecast Similar Waves GapOpen Research Timing Gains Losses Strategies Practice |
| Mon. Apr. 4, 2016 |
Trading Signals: EARS Stock Price Prediction and Forecast (Thu. Mar. 10, 2016 - Thu. Jul. 22, 2021)(Auris Medical Holdin)
| EARS latest price $734.0000 (1.66%) ($710.0000 - $766.0000) on Mon. Apr. 4, 2016. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 4.36% (three month average) | | RSI | 21 | | Latest Price | $734.0000(1.66%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | EARS advances 1.7% a day on average for past five trading days. | | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | | Correlated ETFs | Broad market will support EARS advance at 0% a week (0% probability)
UNG(11%) XLRE(7%) IWN(6%) SDY(6%) EWJ(5%) | | Factors Impacting EARS price | EARS will decline at least -2.18% in a week (0% probabilities).
SKYY(-4%) MCHI(-4%) FXI(-4%) UUP(-3%) KWEB(-3%) | | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.18% (StdDev 4.36%) | | Hourly BBV | 0 () | | Intraday Trend | 1.1% | | | | | |
|
| 5 Day Moving Average | $711.2(3.21%) | | 10 Day Moving Average | $715.13(2.64%) | | 20 Day Moving Average | $0(INF%) | | To recent high | -23.4% | | To recent low | 9.2% | | Market Cap | $N/A | | | | | | |
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.' | $. EARS price fluctuates within INF% (three month std-dev: 4.36%) daily (68% of days).
getNextHourMoveProbability failed |
|